{"preliminary_commentary":{"by_channel":{"x_thread":3,"youtube":2,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["lenalidomide","rituximab"]],"indication":"relapsed/refractory follicular lymphoma","name":"RENOIR","nct_id":"NCT02390869","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=renoir-nct02390869. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"FIL_RENOIR12","arms":[{"description":"A) Rituximab B) Lenalidomide","label":"R2-MANT","type":"EXPERIMENTAL"},{"description":"A) Rituximab","label":"R-MANT","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-08","type":"ESTIMATED"},"conditions":["Lymphoma, Follicular"],"enrollment":{"count":128,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"R2-MANT","otherNames":["Rituximab and Lenalidomide (R2)"],"type":"DRUG"},{"name":"R-MANT","otherNames":["Rituximab (R)"],"type":"DRUG"}],"last_update":"2026-08-19","lead_sponsor":"Fondazione Italiana Linfomi - ETS","official_title":"A Randomized Phase III Multicenter Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-chemotherapy (R-CHT) for Relapsed/Refractory FL Patients Not Eligible for Autologous Transplantation (ASCT).","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2023-01-25","type":"ACTUAL"},"primary_outcomes":[{"measure":"PFS","timeFrame":"2 years from randomization"}],"references":[{"citation":"Botto B, Boccomini C, Evangelista A, Zilioli VR, Anastasia A, Cavallo F, Merli F, Zanni M, Tani M, Chiarenza A, Liberati AM, Conconi A, Rusconi C, Bari A, Del Giudice I, Gaidano G, Spina M, Maschio N, Castellino C, Rota-Scalabrini D, Puccini B, Arcari A, Bigliardi S, Matta GME, Bianchi B, Mannina D, Marino D, Galieni P, Ciambelli F, Musuraca G, Muzi C, Bottelli C, Genuardi E, Meli E, Ferrero S, Luminari S, Ladetto M, Ciccone G, Vitolo U. Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma. Blood Adv. 2026 Jun 25:bloodadvances.2025018732. doi: 10.1182/bloodadvances.2025018732. Online ahead of print.","pmid":"42349017","type":"DERIVED"}],"start_date":{"date":"2014-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients","url":"https://clinicaltrials.gov/study/NCT02390869"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/renoir-nct02390869"}